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Abstract
Background: Pulmonary hypertension (PH) is a disease of multiple etiologies with several common pathological features,
including inflammation and pulmonary vascular remodeling. Recent evidence has suggested a potential role for the
recruitment of bone marrow-derived (BMD) progenitor cells to this remodeling process. We recently demonstrated that
hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMa) is chemotactic to murine bone marrow cells in vitro and involved in
pulmonary vascular remodeling in vivo.
Methodology/Principal Findings: We used a mouse bone marrow transplant model in which lethally irradiated mice were
rescued with bone marrow transplanted from green fluorescent protein (GFP)
+ transgenic mice to determine the role of HIMF in
recruiting BMD cells to the lung vasculature during PH development. Exposure to chronic hypoxia and pulmonary gene transfer
ofHIMFwereusedtoinducePH.BothmodelsresultedinmarkedlyincreasednumbersofBMDcellsinandaroundthepulmonary
vasculature; in several neomuscularized small (,20 mm) capillary-like vessels, an entirely new medial wall was made up of these
cells. We found these GFP
+ BMD cells to be positive for stem cell antigen-1 and c-kit, but negative for CD31 and CD34. Several of
the GFP
+ cells that localized to the pulmonary vasculature were a-smooth muscle actin
+ and localized to the media layer of the
vessels. This finding suggests that these cells are of mesenchymal origin and differentiate toward myofibroblast and vascular
smooth muscle. Structural location in the media of small vessels suggests a functional role in the lung vasculature. To examine a
potentialmechanism for HIMF-dependent recruitment of mesenchymal stem cells tothe pulmonary vasculature, weperformed a
cell migration assay using cultured human mesenchymal stem cells (HMSCs). The addition of recombinant HIMF induced
migration of HMSCs in a phosphoinosotide-3-kinase-dependent manner.
Conclusions/Significance: These results demonstrate HIMF-dependent recruitment of BMD mesenchymal-like cells to the
remodeling pulmonary vasculature.
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Introduction
Hypoxia-induced mitogenic factor (HIMF), also known as ‘‘found
in inflammatory zone 1’’ (FIZZ1) and resistin-like molecule alpha
(RELMa), is a pleiotropic cytokine that is highly inducible in lung
[1–3]. We have shown it to have mitogenic, angiogenic, vasocon-
strictive, and chemokine-like properties [3–6]. We initially described
HIMF in the remodeling vasculature of the chronic hypoxia model of
pulmonary hypertension (PH) [3] and have recently determined that
HIMF plays a critical role in this process [7]. In rats, in vivo
knockdown of HIMF specifically in the lung reduces the mean
pulmonary artery pressure, pulmonary vascular resistance, and
vascular remodeling associated with chronic hypoxia, whereas
pulmonary gene transfer of HIMF initiates vascular remodeling
and increases these physiological measurements [7]. Liu et al. [8] has
shown that HIMF plays a key role in the transition of fibroblasts to
myofibroblasts, which is essential to bleomycin-induced fibrosis and
may play a role in vascular remodeling associated with PH. Our lab
and others have demonstrated that the addition of recombinant
HIMF to cultured cells activates the phosphoinosotide-3-kinase (PI-
3K)/Akt and extracellular signal-regulated kinase 1/2 (ERK1/2)
mitogen-activated kinase (p42/44 MAPK) pathways in several
different cell types [3,9,10]. Finally, we have demonstrated that
HIMF is chemotactic for undifferentiated murine bone marrow-
derived (BMD) cells and this action is mediated through Bruton’s
tyrosine kinase (BTK) [5].
Pulmonary vascular remodeling is a key component of the
pathogenesis of PH. Recent evidence has suggested the possibility
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process [11,12]. Davie et al. [11] demonstrated that BMD c-kit
+
cells were localized within the pulmonary artery walls of
chronically hypoxic calves, and Spees et al. [12] reported that a-
smooth muscle actin (a-SMA)
+ BMD cells became engrafted into
the pulmonary vasculature in an inflammatory model of PH.
These studies suggest the interesting possibility that pulmonary
vascular remodeling may involve cells of multiple origins, possibly
including multipotent ‘‘stem cells.’’
In the current study, we demonstrate in mice that both chronic
hypoxia and pulmonary gene transfer of HIMF induce BMD cell
recruitment to the remodeling pulmonary vasculature; many of
these cells localize to the newly formed media of previously non-
muscularized capillary-like vessels. Both mouse models led to
significant pulmonary vascular remodeling consistent with our
prior demonstration of structural and hemodynamic PH. We
describe several of these cells to be stem cell antigen (sca)-1
+ and
c-kit
+ as well as CD31
2 and CD34
2. The BMD cells located
within the vessel walls are likely of mesenchymal origin as they
are a-SMA
+. We also show that HIMF induces migration of
human mesenchymal stem cells (HMSCs) in a PI-3K-dependent
manner in vitro. All of these data suggest that HIMF/FIZZ1/
RELMa recruits BMD cells to the remodeling pulmonary
vasculature.
Materials and Methods
Experimental animals/bone marrow transplantation
Female C57/BL6 mice (6–8 weeks old; Charles River
Laboratories, Wilmington, MA) were used as bone marrow
transplant recipients for all experiments. Four- to 6-week-old
male transgenic enhanced green fluorescent protein (EGFP) mice
on a C57BL/6 background (Jackson Laboratories, Bar Harbor,
ME; stock number: 003291) were used as bone marrow donors
[13]. Animal housing and experimental protocols were approved
by the Animal Care and Use Committee of the Johns Hopkins
University (Protocol #: MO08M424). The mice were given free
access to food and water and were maintained in a room with a
12:12 hour light-dark cycle between 20–24uC. Bone marrow
transplants were performed as previously stated [14]. Briefly,
whole bone marrow was collected from the transgenic EGFP mice,
and 2610
6 bone marrow cells were transplanted into lethally
irradiated (1,050 cGy) recipient mice through intravenous
injection. The transplant recipients were then allowed to recover
for 4–6 weeks.
Antibodies and Inhibitors
Rabbit anti-mouse HIMF polyclonal antibodies were prepared
as we have described [3]. Polyclonal rabbit anti-GFP antibodies
were purchased from Invitrogen (Carlsbad, CA). Goat anti-mouse
RELMa (HIMF), rat anti-mouse c-kit, and rat anti-mouse sca-1
antibodies were purchased from R&D Systems (Minneapolis,
MN). The rat anti-mouse CD31 and the mouse anti-b-actin
monoclonal antibodies were purchased from BD Biosciences (San
Jose, CA). The rabbit anti-CD34 antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The mouse anti-a-
SMA antibody was purchased from DakoCytomation (Carpin-
teria, CA). Fluorescein isothiocyanate (FITC), rhodamine, cy3-
and cy5-labeled secondary antibodies were purchased from
Jackson ImmunoResearch (West Grove, PA). The rabbit anti-
phospho-Akt (Ser473/Thr308) and rabbit anti-phospho-ERK1/2
(Thr202/Tyr204) polyclonal antibodies as well as the pharmaco-
logical inhibitors U0126 and LY294002 were purchased from Cell
Signaling Technologies, Inc. (Beverly, MA).
Intranasal instillation of viral vectors
To selectively induce HIMF expression in the lungs, we used a
recombinant adeno-associated virus (AAV) vector that expresses
murine HIMF (AAV-HIMF) as stated [7]. This viral vector
contains the ubiquitous CB promoter and was prepared by the
University of Florida Vector Core Laboratory. To control for the
possibility of viral effects, we used a similar empty AAV vector
(AAV-null). Intranasal instillation of the AAV vectors was
performed as follows. First, female bone marrow transplant
recipient mice were lightly anesthetized with isoflurane. Then, a
gel loading tip primed with 50 mL of solution that contained either
2.5610
10 viral particles (VP) AAV-HIMF [with 5 mL lipofecta-
mine 2000 (Invitrogen)] or 2.5610
10 VP AAV-null (with 5 mL
lipofectamine 2000) was placed directly on the nasal passage and
the solution expelled. Mice were sacrificed 14 days after intranasal
instillation of the vector by isoflurane overdose, and tissue was
processed as stated [7]. Briefly, the heart and lungs were removed
en bloc. The right lung was tied off and the left lung was inflated
with 1% low-melting point agarose with constant pressure and
then placed on ice. The right lung was removed and split into
individual lobes. A portion of the right lung was frozen in liquid N2
and stored at 280uC for use in Western blot analysis. The
agarose-filled lung tissue was fixed in 4% paraformaldehyde and
then processed for either paraffin or frozen sections as stated [3,7].
The efficiency of instillation was measured by Western blotting or
immunohistochemistry for HIMF.
Chronic hypoxia model of PH
Female mice receiving bone marrow transplantation were
exposed to either normal room air (20.8% O2) or 10% O2 for 7
days as we have described [3,7,15–18]. The fractional concentra-
tion of O2 was monitored and controlled with a Pro:Ox model 350
unit (Biospherix, Redfield, NY) by infusion of N2 (Roberts
Oxygen, Rockville, MD) balanced against an inward leak of air
through holes in the chamber. The chambers were continuously
scavenged for CO2 and ammonia. At the end of the 7-day period,
mice were sacrificed and processed as stated above.
Immunohistochemistry
Paraffin blocks of lungs from mice exposed to room air
(20.8%O2), hypoxia (10.0% O2), AAV-null, or AAV-HIMF were
cut into 6-mm sections and placed onto clean glass slides. The
slides were then deparaffinized and rehydrated as described
previously [3,7]. For antigen retrieval, the slides were submerged
in antigen unmasking solution (Vector Laboratories, Burlingame,
CA) and heated at 95uC for 20 min. Endogenous peroxidase
activity was blocked by treatment with 3% H2O2 in PBS for
10 min at room temperature (RT). We then blocked endogenous
avidin and biotin for 15 min each at RT using the Avidin/Biotin
Blocking Kit (Vector Laboratories). Nonspecific protein binding
was blocked by treatment with either normal goat or horse serum
for 30 min at RT. After the blocking steps, the sections were
treated with polyclonal rabbit anti-GFP antibodies, polyclonal
goat anti-HIMF antibodies, or antibody diluent alone for 2 h at
RT. The slides were then washed with PBS and treated with either
goat anti-rabbit or donkey anti-goat biotinylated secondary
antibodies (Vector Laboratories) in PBS for 30 min at RT. Then,
the lung sections were exposed to an ABC horseradish peroxidase
(HRP) reagent (Vector Laboratories) for 30 min at RT. The GFP/
HIMF signal was developed with the Peroxidase Substrate Kit
DAB (Vector Laboratories). The sections were counterstained with
hematoxylin as we have described [7]. Finally, the sections were
dehydrated, cleared, and mounted with Cytoseal 60 (Richard-
Allan Scientific, Kalamazoo, MI). The stained sections were
HIMF and Stem Cells
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QImaging Retiga 4000RV digital camera. Images were captured
with ImagePro Plus (version 5.1) software.
Quantification of GFP-positive cells
To quantify the number of GFP
+ cells associated with the
pulmonary vasculature, the GFP-stained lung sections were
examined with a 406 objective lens. Peripheral pulmonary
arteries associated with alveolar sacs and alveolar ducts with an
external diameter between 25 and 100 mm were identified, and the
associated GFP
+ cells were counted. GFP
+ cells were quantified in
approximately 50 consecutive vessels per animal. The values are
expressed as the mean number of GFP
+ cells per vessel (mean 6
SEM).
Assessment of pulmonary vascular remodeling
Pulmonary vascular remodeling of the mice was analyzed as we
have previously described [7,15–18]. The murine lung sections
were initially evaluated after being stained with hematoxylin and
eosin. Lung sections were also dual stained with von Willebrand
Factor (endothelium) and a-SMA (vascular smooth muscle) as we
have described [7,17,18]. Upon completion of the dual-stain,
approximately 100 randomly selected arteries were examined
under an Olympus-BHS microscope attached to a QImaging
Retiga 4000RV digital camera. Only arteries with an internal
diameter of ,80 mm were examined. These vessels were classified
as non-muscular (NM), partially-muscular (PM), or fully-muscular
(FM), according to a-SMA staining. Vessels that had at least one
a-SMA
+ cell but lacked a continuous layer were considered PM.
FM vessels had a continuous a-SMA band. These vessels were
then analyzed as we have described [7,17,18]. Images of dual-
stained sections were captured as stated above.
Immunofluorescence microscopy
Frozen lung sections were air dried for 30 min, permeabilized
with 0.2% Triton X-100/PBS, and then blocked with 2% BSA/
PBS. The sections were exposed to primary antibody (c-kit, sca-1,
CD31, CD34, a-SMA, or HIMF) followed by the appropriate
secondary antibody (cy3-donkey anti-rabbit IgG, cy3-donkey anti-
rat IgG, FITC-donkey anti-mouse IgG, or cy5-donkey anti-mouse
IgG). Nuclei were stained with 50 ng/mL 49,69-diamidino-2-
phenylindole dilactate (DAPI) for 5 min. Staining was imaged with
a Zeiss 510 Meta confocal microscope via a 206lens. When four
channels were used, cy5 was labeled with pink. Differential
interference contrast imaging was used to show the tissue
structure.
In vitro Cell Migration Assay
HMSCs were purchased from Lonza (Walkersville, MD) and
cultured according to the manufacturer’s specifications. Only
HMSCs from passages 3–5 were used. Costar 24-well cell migration
plates with polycarbonate membranes with 8-mm pore size (Costar
Corporation, Cambridge, MA) were used for this assay. The lower
chamber was filled with 0.6 mL of medium with or without
100 nM recombinant HIMF. Then, 100 mL of HMSC suspension
(10
5 cells) was added to the upper chamber. In some experiments,
the cells were pretreated for 30 min with vehicle (0.1% DMSO) or
a pharmacological kinase inhibitor [U0126 (10 mM) or LY294002
(10 mM)]. After 24 h at 37uC, the cells were removed from the top
surface of the membrane. Migrated cells on the bottom surface
were stained with Coomassie blue. The average number of cells
per field was evaluated under an Olympus-BHS microscope.
Images were captured with a QImaging Retiga 4000RV digital
camera, analyzed by NIH ImageJ software, and reported as the
number of positively stained pixels versus the total number of
image pixels.
Western Blot Analysis
HMSCs were cultured to approximately 70% confluence and
then serum- and growth factor- starved overnight. Then they were
treated with vehicle or 100 nM HIMF for various time periods in
the presence or absence U0126 (10 mM) or LY294002 (10 mM).
The HMSCs were collected in equal volumes of Laemlli’s sample
buffer, resolved by 4–20% gradient sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad), and
transferred to nitrocellulose membranes (Bio-Rad). The blots were
blocked with 5% non-fat milk-TBS-T and incubated with either
rabbit anti-phospho-Akt (Ser473/Thr308) or rabbit anti-phospho-
ERK1/2 (Thr202/Tyr204) antibody. The blots were then
incubated with anti-rabbit IgG conjugated to HRP antibodies,
developed with enhanced chemiluminescence (ECL) and exposed
to X-ray film (Denville Scientific; Metuchen, NJ). To ensure equal
protein loading and transfer, the blots were stripped using the Blot
Restore kit according to the manufacturer’s instructions (Millipore;
Billerica, MA), reprobed with mouse anti-b-actin antibodies and
processed as stated above.
Statistical analysis
A student’s t-test was used to compare mean responses between
individual experimental and control groups. ANOVA was used to
compare the mean responses among experimental and control
groups in experiments with multiple groups. The Dunnett and
Scheffe F test was used to determine between which groups
significant differences existed. A P-value ,0.05 was considered
significant for all experiments.
Results
Hypoxia and pulmonary HIMF gene transfer induce HIMF
expression in bone marrow transplant recipient mice
To determine the expression pattern of HIMF in our bone
marrow transplant recipients, we evaluated lung sections from mice
exposed to normoxia (7d, 20.8% O2), hypoxia (7d, 10.0% O2),
AAV-null (14d, 2.5610
10 VP), or AAV-HIMF (14d, 2.5610
10 VP)
by immunohistochemistry. Both hypoxia and HIMF pulmonary
gene transfer led to HIMF expression in the lungs of bone marrow
transplant recipients (Figure 1). In normoxic lungs, HIMF staining
was not apparent (Figure 1A), but HIMF was strongly expressed in
the airway epithelium, pulmonary inflammatory cells, and pulmo-
nary vasculature of hypoxic animals (Figure 1B). In the HIMF gene
transfer experiments, HIMF staining was absent in AAV-null
treated lungs (Figure 1C) but strong in airway epithelium and the
pulmonary vasculature (Figure 1D). The introduction of AAV-null
virus into the lungs did not change HIMF expression compared to
normoxic control (Figure 1A, C).
BMD cells are localized to the pulmonary vasculature
Immunostaining for GFP with subsequent quantitative analysis
showed that in both hypoxic and AAV-HIMF-treated bone
marrow transplant recipients, increased numbers of GFP
+ cells
became associated with the vasculature (Figure 2) compared to
appropriate simultaneous controls. Visual examination of both
hypoxic and AAV-HIMF-treated lung sections revealed GFP
+
cells associated with the vasculature; in comparison, relatively few
GFP
+ cells were associated with the pulmonary vasculature of
normoxic or AAV-null treated mice (Figure 2A–D). Notably, mice
from all groups had some GFP
+ cells evenly distributed throughout
HIMF and Stem Cells
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[19] or possibly representing normal distribution of inflammatory
BMD cells in lung. Quantification of the GFP
+ cells associated
with individual pulmonary vessels confirmed the visual findings.
Our analysis revealed approximately twice as many GFP
+ cells/
vessel in hypoxic mice (1.1360.09 GFP
+ cells/vessel) compared
with normoxic mice (0.6360.05 GFP
+ cells/vessel; P=0.0005;
Figure 2E). Similarly, the number of GFP
+ cells/vessel in AAV-
HIMF-treated mice (1.0960.14 GFP
+ cells/vessel) was greater
than that of AAV-null-treated mice (0.5860.09 GFP
+ cells/vessel;
P=0.0266; Figure 2F). The result of AAV-HIMF treatment looks
strikingly similar with hypoxia; HIMF gene transfer was sufficient
to induce the recruitment of BMD cells to the pulmonary
vasculature (Figure 2). To gain a different visual perspective of
these lung sections, we performed immunofluorescence microsco-
py using lung sections from each group. Figure 3A–I shows that
after either hypoxia or AAV-HIMF treatment, GFP
+ BMD cells
formed an organized layer that surrounded the blood vessel. A
cross sectional view is shown in Figure 3J–U. A higher
magnification image of a small vessel from an AAV-HIMF treated
mouse revealed that the entire media layer of the neomuscularized
small vessel was made up of GFP
+ BMD cells (Figure 3M, Q, U).
Most of the recruitment of GFP
+ cells was observed in small vessels
approximately 20–80 mm in diameter, including small capillary
sized vessels normally without any muscle cells. This is strong
evidence of a functional role of these cells in the remodeling
pulmonary vasculature and the development of PH.
Hypoxia and AAV-HIMF treatment similarly increased
pulmonary vascular remodeling
In the bone marrow transplant recipients, muscularization of
the small pulmonary arteries was increased by both hypoxia and
AAV-HIMF treatment compared to the corresponding controls
(Figure 4A–D). After exposure to 10.0% O2 for 7 days, the
percentage of vessels that were FM increased (30.3163.46% vs.
7.9664.30%; P=0.0018), while the percentage of vessels that
were NM decreased (30.5264.78% vs. 57.46611.19%;
P=0.0392) compared with control animals exposed to room air
(Figure 4E). Examination of the lung sections 14 days after
intranasal instillation of AAV-HIMF revealed increased percent-
ages of FM vessels (15.05611.19%) when compared to simulta-
neously treated AAV-null controls (5.2962.64%; P=0.0187;
Figure 4F).
BMD cells are recruited to the smooth muscle layer of
pulmonary vessels
To determine the phenotype of recruited cells in AAV-HIMF-
treated lungs, we used the markers sca-1, c-kit, CD34, CD31, and
a-SMA. The markers sca-1 and c-kit indicate that the cells are of
Figure 1. HIMF expression in murine lung. Paraffin-embedded lung sections from normoxic (7d, 20.8% O2) (A), hypoxic (7d, 10.0% O2) (B), AAV-
null-treated (14d, 2.5610
10 VP) (C), and AAV-HIMF-treated (14d, 2.5610
10 VP) (D) mice were rehydrated and stained with goat anti-mouse HIMF
polyclonal antibodies. Pa: pulmonary artery. Aw: airway. Scale bar: 50 mm.
doi:10.1371/journal.pone.0011251.g001
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CD34 are prominent markers for cells of endothelial lineage.
Finally, a-SMA indicates cells of mesenchymal origin. As shown in
Figure 5, GFP
+ BMD cells recruited to the vasculature were sca-1
+
(Figure 5B, D) and c-kit
+ (Figure 5F, H). Some sca-1
+ and c-kit
+
cells contained no GFP signal; these cells are likely unlabeled
BMD cells, as not all of the BMD cells from the GFP transgenic
donor express GFP [13]. Surprisingly, none of the GFP
+ cells
associated with the vasculature were also CD34
+ (Figure 5J, L). To
determine at which layer of the vasculature the GFP
+ cells were
located, we performed immunohistochemical staining for both a-
SMA (vascular smooth muscle) and CD31 (endothelium). As
shown in Figure 6, the GFP
+ cells appeared to be recruited to the
smooth muscle layer of the vasculature. GFP and a-SMA signals
colocalized in many vascular cells that anatomically appeared to
associate with the smooth muscle layer (Figure 6C, D; arrows).
These signals also co-localized with HIMF (Figure 6B). There was
no apparent co-localization between GFP and the endothelial cell
marker, CD31 (Figure 6A, B).
HIMF-stimulated HMSC chemotaxis is
Akt/PI-3K-dependent
To examine if HIMF has a direct effect on mesenchymal stem
cells, we performed a cell migration assay using HMSCs. For these
experiments, HMSCs were cultured in transwell plates in the
presence of vehicle or recombinant HIMF (100 nM) for 24 h.
HIMF increased HMSC migration approximately 2-fold
(Figure 7). We have previously shown that HIMF can induce
activation of both the Akt/PI-3K pathway and the ERK1/2
MAPK pathway in vitro [3]. To determine if HIMF activated these
pathways in HMSCs, we treated cultured HMSCs that had been
serum and growth factor starved overnight with vehicle or HIMF
(100 nM) for 15 or 60 min. The addition of HIMF activated both
the PI-3K and ERK1/2 MAPK pathways in a time-dependent
manner (Figure 7C, D). Because HIMF induced cell migration and
activated these signaling pathways in HMSCs, we wanted to
determine if one or both of these pathways were involved in
HIMF-induced cell migration. Preincubation of HMSCs with the
PI-3K inhibitor LY294002 (10 mM) returned HIMF-induced cell
migration to baseline levels (Figure 7B); inhibition of ERK1/2
MAPK with the pharmacological inhibitor U0126 (10 mM) had a
slight, but not statistically significant effect (Figure 7B). In
Figure 7C and 7D, we demonstrate that both LY294002 and
U0126 successfully entered the HMSCs and blocked the
appropriate signaling pathway.
Discussion
In the current study, we examined the possibility that HIMF/
FIZZ1/RELMa acts as a chemokine to induce BMD cell
recruitment to the remodeling pulmonary vasculature. To address
this question, we transplanted bone marrow from GFP
+ transgenic
mice [13] into lethally irradiated wild-type recipients, subjected
the recipients to models of PH, and tracked BMD cell migration
[14] in the pulmonary vasculature. The results show that both
chronic hypoxia and AAV-HIMF introduction induce PH-like
vascular remodeling and the engraftment of BMD cells to the
pulmonary vasculature. Further analysis of the recruited BMD
cells in AAV-HIMF-treated mice revealed that many of these cells
expressed c-kit, sca-1, and a-SMA and lacked expression of CD31
Figure 2. Chronic hypoxia and pulmonary HIMF gene transfer increase the number of BMD cells associated with the pulmonary
vasculature. A–D: Paraffin-embedded lung sections from mice exposed to normoxia (7d, 20.8% O2) (A), hypoxia (7d, 10.0% O2) (B), AAV-null (14d,
2.5610
10 VP) (C), or AAV-HIMF (14d, 2.5610
10 VP) (D) were probed with polyclonal antibodies raised against GFP. Arrows indicate GFP
+ cells within
the vasculature. Scale bar: 50 mm. E, F: Quantification of GFP
+ cells within the pulmonary vasculature. GFP
+ cells within the pulmonary vasculature are
shown as mean 6 SEM of GFP
+ cells/vessel. * P,0.05, ** P,0.01 vs. control.
doi:10.1371/journal.pone.0011251.g002
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mesenchymal in origin and have the capacity to differentiate into
myofibroblast-like cells and possibly vascular smooth muscle cells.
We also show that HIMF has a direct effect on HMSCs by
increasing cell migration in a PI-3K-dependent manner. Together,
these findings demonstrate that HIMF/FIZZ1/RELMa plays an
important role in the recruitment and engraftment of BMD cells in
pulmonary vascular remodeling.
We have previously described HIMF expression in proliferating
cell nuclear antigen (PCNA)-positive cells, vascular smooth muscle
cells, and endothelial cells of the remodeling vasculature in animals
with chronic hypoxia-induced PH [3]. We have also demonstrated
that AAV-HIMF pulmonary gene transfer leads to HIMF
expression in the vascular smooth muscle and endothelium of
lung vessels (all sizes), bronchial epithelial cells, and alveolar type II
cells [7]. The HIMF expression pattern in bone marrow transplant
recipients used in this study was consistent with our previous work
that showed increased HIMF in the actively dividing pulmonary
vascular endothelial and smooth muscle cells following hypoxic
exposure or pulmonary AAV-HIMF treatment [3,7]. We also
have recently demonstrated that HIMF plays a key role in
hypoxia-induced pulmonary vascular remodeling; we can induce
pulmonary vascular remodeling and the hemodynamic and
cardiac hypertrophic changes of PH by pulmonary gene transfer
of HIMF [7]. In the current study, we demonstrate that hypoxia
and intranasal instillation of AAV-HIMF induce the same pattern
of muscularization of small pulmonary arteries.
It is largely unknown whether the pulmonary vascular
remodeling involves the proliferation of resident vascular cells,
transition of other resident lung cells to stem cells critical to
remodeling, or recruitment of BMD cells and stem cells to the
lung. This is an area of considerable controversy. Many recent
studies have shown that BMD cells are involved in tissue
remodeling and repair of several organs, including the lung [20].
These cells have also been shown to be localized in atherosclerotic
lesions of the vasculature [21,22]. In fact, human patients who
Figure 3. Both chronic hypoxia and pulmonary HIMF gene transfer recruit BMD cells to the pulmonary vasculature. (A–C, J–M) Light
micrograph of fluorescence images to show blood vessel structure. Frozen sections from normoxic (20.8% O2) (D, N), hypoxic (10.0% O2) (E, O), and
AAV-HIMF treated (2.5610
10 VP) (F, P, Q) lungs were stained with a rabbit anti-GFP polyclonal antibody that was visualized by an FITC-conjugated
goat anti-rabbit IgG antibody (green). (G–I, R–U): Differential interference contrast images of light and fluorescence images to show structure. A–L, N–
P, R–T: Scale bar: 50mm. M, Q, U: Scale bar: 20mm.
doi:10.1371/journal.pone.0011251.g003
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within their vasculature [23]. In our study, we demonstrate that
GFP
+ BMD cells are recruited to the pulmonary vasculature
following chronic hypoxia or overexpression of HIMF in the lung.
In fact, there are nearly twice as many GFP
+ BMD cells associated
with the vessels from mice exposed to chronic hypoxia or AAV-
HIMF. In pulmonary vessels from normoxia/AAV-null control
mice, there is almost never more than one GFP
+ cell associated
with an individual vessel. These GFP
+ cells are rarely incorporated
into the media layer in the vessels of these mice. In the
experimental groups (chronic hypoxia or AAV-HIMF), it is
common for some pulmonary vessels to have multiple associated
GFP
+ cells with these cells frequently localizing to the medial layer
of the vessel. In several cases, these BMD cells aggregate around
previously endothelial-only capillary vessels; neomuscularization of
these vessels are a key component of the pathogenesis of PH.
Recent evidence has suggested a potential role for the
recruitment of BMD progenitor cells to the remodeled pulmonary
vasculature associated with PH [11,12,24]. An initial study by
Davie et al. [11] revealed an increased number of c-kit-expressing
cells in the circulation and in the pulmonary vasculature of
hypoxic calves. C-kit, also known as CD117, is the receptor for a
cytokine called stem cell factor; it is expressed on the surface of
BMD cells with multipotent potential [25]. A subsequent study by
Hayashida et al. [24] demonstrated that mice exposed to chronic
hypoxia for 4 or 8 weeks displayed increased infiltration of BMD
cells in the lung and lung vasculature compared with normoxic
control. Many of these recruited BMD cells were a-SMA
+.
Hypoxia does not seem to be the only stimulus for this process; in
the monocrotaline inflammatory model of PH, many BMD cells
were recruited to the pulmonary vasculature, some of which were
a-SMA
+ [12]. A detailed examination of AAV-HIMF-treated
lungs showed that many of the recruited cells stained positive for
the cellular markers c-kit and sca-1. This finding would indicate
that these BMD cells have multipotent potential, including the
ability to differentiate into mesenchymal-like cells; these differen-
tiated cells could then participate in the observed pulmonary
vascular remodeling. The fact that these cells were negative for the
endothelial progenitor markers CD31 and CD34 strengthens the
possibility that these cells will likely differentiate into mesenchy-
mal-like cells. Several of the GFP
+ cells associated with the
pulmonary blood vessels also expressed a-SMA, indicating a
mesenchymal lineage and suggesting the possible transition to
myofibroblasts and vascular smooth muscle cells. The fact that
many of the smallest neomuscularized vessels expressed only GFP
+
cells in their new medial layer, strongly suggests a functional role
for these cells. This work supports the ability of HIMF to recruit
BMD cells to the vascular wall in the remodeling associated with
the development of PH.
We have recently demonstrated that HIMF is chemotactic for
murine BMD cells in culture [5] and that the mechanism involves
HIMF binding to BTK, resulting in BTK autophosphorylation
and intracellular movement of BTK to the migrating cell process.
Here, we showed that HIMF expression in the lung can recruit
BMD cells to the remodeling pulmonary vasculature and that
HIMF induces chemotaxis of HMSCs in culture. These results are
consistent with our earlier findings and those of previously
published reports [11,24] in which chronic hypoxia induced
vascular remodeling. Intranasal AAV-HIMF treatment elicited
similar results.
Figure 4. Both chronic hypoxia and pulmonary HIMF gene transfer induce pulmonary vascular remodeling. A–D: Paraffin-embedded
lung sections were double-stained with antibodies to von Willebrand factor (black) and a-smooth muscle actin (red). Arrows indicate small pulmonary
vessels. Scale bar: 50 mm. E, F: Percent muscularization of small pulmonary arteries in mouse lungs. NM, non-muscularized; PM, partially muscularized;
FM, fully muscularized. *Significantly decreased vs. control at P,0.05.
{Significantly increased vs. control at P,0.05.
doi:10.1371/journal.pone.0011251.g004
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11251Figure 5. GFP and cellular markers sca-1 and c-kit co-localize in AAV-HIMF-treated bone marrow transplant recipients. Frozen lung
sections from bone marrow transplant recipients treated with AAV-HIMF (2.5610
10 VP, 14d) were stained with antibodies for (B) sca-1, (F) c-kit, or (J)
CD34 (red). (C, G, K) GFP signal was obtained through direct visualization (green). (A, E, I) Cell nuclei were counterstained with DAPI (blue). (D, H, L)
The arrows in the merged images demonstrate co-localization of GFP with the cellular markers. Scale bar: 20 mm.
doi:10.1371/journal.pone.0011251.g005
Figure 6. GFP
+ cells were recruited to the smooth muscle layer of the pulmonary vasculature in AAV-HIMF-treated mice. GFP was detected
through direct visualization (A, E; green). HIMF and a-smooth muscle actin (a-SMA) were detected with anti-HIMF and anti-a-SMA primary antibodies and
visualized with rhodamine-conjugated anti-rabbit IgG secondary antibodies (B; red) and Cy5-conjugated anti-mouse IgG secondary antibodies (C; pink),
respectively. Arrows in the merged image indicate co-localization of GFP, HIMF, and a-SMA (D). Lung sections were stained with anti-CD31 antibodies and
visualized with rhodamine-conjugated anti-rat IgG antibodies (F; red) and anti-a-SMA antibodies and visualized with Cy5-conjugated anti-mouse IgG
antibodies (G, pink). (F) Arrows in the merged image indicate co-localization of GFP anda-SMA. Cell nuclei were stained with DAPI (D, H; blue) Scale bar: 20 mm.
doi:10.1371/journal.pone.0011251.g006
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study raises the possibility that HIMF directly recruits mesenchy-
mal stem cells to the remodeling pulmonary vasculature. Previous
studies have demonstrated the existence of circulating BMD
smooth muscle cells and the potential vascular engraftment of
these cells in human disease [21,23]. In our system, we showed
that these cells are of mesenchymal lineage and directly engraft
into the vascular wall. It is important to note the possibility that
HIMF is driving these recruited cells to the mesenchymal lineage.
HIMF has been shown to play a key role in the transition of
fibroblasts to myofibroblasts in experimentally-induced pulmonary
fibrosis [8]. It is likely that the cells that are currently c-kit
+ and
sca-I
+ will transition into vascular smooth muscle cells in the
remodeling vasculature.
A receptor for HIMF or its related molecules has not yet been
described, although a few signaling pathways have been identified.
We have previously reported that HIMF activates the PI-3K
pathway in pulmonary vascular smooth muscle cells in a dose- and
time-dependent manner [3]. We have also demonstrated that
HIMF activates the Akt/PI-3K pathway in endothelial cells; this
activation plays a critical role in HIMF-induced endothelial
migration and tubule formation [6]. Other groups also have shown
this pathway to be activated in primary lung fibroblasts as well as
endothelial and lung epithelial cell lines [9,10]. Here we showed
that HIMF activates the PI-3K pathway in a time-dependent
manner in primary HMSCs and that this pathway is involved in
HIMF stimulated cell migration. One signaling pathway that
activates the Akt/PI-3K pathway in several cellular systems is
BTK [26]. Our previous studies have shown that HIMF is a
binding partner for BTK as well as an activating agent in murine
BMD cells [5]; intracellular movement of BTK to the migrating
cell process is essential to HIMF-induced cell migration of these
cells. It is possible that HIMF is activating Akt/PI-3K through the
BTK pathway in this system. HIMF also activated ERK1/2
MAPK in a time-dependent manner in HMSCs, but this pathway
did not appear to be involved in the HIMF-stimulated cell
migration process.
In summary, the current study demonstrates that pulmonary
gene transfer of HIMF induces pulmonary vascular remodeling
and the recruitment of BMD cells to the pulmonary vasculature
similar to that of chronic hypoxia. Cells that were recruited to the
vasculature were c-kit
+, sca-1
+, and a-SMA
+, but CD31
2 and
CD34
2; these results suggest that these recruited cells are BMD
and mesenchymal in origin or have the potential to differentiate
into mesenchymal-like cells that participate in pulmonary vascular
remodeling. The study also shows that HIMF has direct action on
Figure 7. HIMF-stimulated HMSC migration is PI-3K-dependent. A: HMSCs (10
5 cells) were cultured in the upper chamber of a transwell plate;
the lower chamber held medium containing BSA (control) or HIMF (100 nM). After 24 h, the cells were fixed and stained by Coomasie blue solution. B:
HMSCs were grown as described in A, but cells were pretreated with vehicle, U0126 (10 mM), or LY294002 (10 mM). Migrated cells were quantified and
results were reported as mean (6SEM) of area (pixels). *Significant increase vs. vehicle control at P,0.05.
{Significant decrease vs. HIMF stimulation
alone at P,0.05. C, D: HMSCs were cultured to approximately 70% confluence, serum and growth factor starved overnight, and then exposed to
HIMF (100 nM) or vehicle for up to 60 min in the presence or absence of ERK1/2 MAPK inhibitor U0126 (10 mM) or PI-3K inhibitor LY294002 (10 mM).
Cells were lysed and proteins were resolved with SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with rabbit
anti-phospho-ERK1/2 (Thr202/Tyr204) (C) or rabbit anti-phospho-Akt (Ser473/Thr308) (D), followed by HRP-conjugated anti-rabbit IgG antibodies, and
developed with ECL. To ensure equal loading and transfer, blots were stripped and reprobed with anti-b-actin.
doi:10.1371/journal.pone.0011251.g007
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PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11251HMSCs by inducing PI-3K-dependent chemotaxis. Taken
together, these data suggest that HIMF plays an important role
in the recruitment of BMD cells to the remodeling pulmonary
vasculature.
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